Prof. Dr. Liping Yang, MD, CEO and Founder

The leading figure in the HiST pharmaceutical section, Prof. Dr. Liping Yang, started as an ordinary medical doctor and a chief physician with little national or international fame in the pharmaceutical industry. He leveraged his extensive experience in traditional and modern medicine, which he had accumulated through decades of frontline clinical and medical practice, to found HiST Pharma. This forward-looking venture capitalized on his deep expertise in drug discovery, medical practice, and entrepreneurship.

Prof. Yang has been deeply involved in patient care for decades, attending to numerous individuals and gaining firsthand insights into various therapeutic approaches. Breaking away from conventional approaches, he integrates the rich heritage of Traditional Chinese Medicine (TCM) with modern science and technologies to develop state-of-the-art drugs and integrative therapies for immune-related diseases like psoriasis. This involved utilizing the latent therapeutic potential of botanical plants and extracting active pharmaceutical ingredients (APIs) well-known for their high efficacy and safety. By combining empirical clinical applications of these naturally occurring botanicals with modern immunological technologies and evidence-based translational medicine, Prof. Yang successfully developed TC Cream—HiST Pharma’s flagship product and the world’s first botanicalbased small-molecule drug for the prevention and treatment of psoriasis vulgaris and other immune-mediated inflammatory skin conditions. “Our drug, derived from plants, embodies purity. Its well-characterized APIs ensure safety and efficacy, offering relief and reassurance and empowering patients to trust its long-term benefits without hesitation,” says Prof. Yang.

TC Cream—formulated for topical application—offers a holistic remedy, harnessing the potency of plantbased compounds to modulate both local and systemic immunities. Multiple multi-center and large-population randomized clinical trials have been rigorously conducted to confirm its efficacy, enabling it to secure approval from regulatory bodies like China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). TC Cream will serve as a lifeline for millions worldwide, promising safe and effective relief from psoriatic symptoms.

Advocating for a Systematic Approach to Promote the Exploration of Psoriasis Prevention and Long-term Management

The World Health Organization (WHO) has categorized psoriasis as a chronic, painful, disfiguring, and disabling noncommunicable disease (NCD) with no definite cause or cure. Psoriasis impacts over 100 million people across all age groups and countries, with reported rates ranging from 0.09 to 11.43 percent, making it a worldwide concern.

Traditional treatments for psoriasis, which primarily rely on immunosuppressants or biologics targeting specific immunomodulators, bear significant risks and long-lasting implications. Venturing beyond conventional approaches, HiST Pharma has pioneered global immunomodulatory topical drugs and therapeutic modalities that address the underlying immunological pathways involved in psoriasis pathogenesis.

The modalities are based on TCM’s foundational principles, such as natural compounds, holistic approaches, dialectical treatment, and disease prevention. According to these principles, a local medical condition should not be viewed in isolation but systemically interconnected with the entire human body, fostering harmony between individuals and disease conditions. Rather than passively awaiting the symptoms, HiST Pharma promotes proactive prevention, developing formulations considering the body’s internal dynamics and external influences shaping one’s health.

“HiST Pharma aims to address the unmet needs of patients grappling with immune-mediated diseases and create positive social and economic impacts,” says Prof. Yang.

Pioneering Reverse Drug Discovery
HiST Pharma does not just develop innovative products; it enables a visible shift in psoriasis treatment. While the TC targets mild-to-moderate cases, the company’s comprehensive therapy and prevention protocol goes beyond symptomatic relief to address the genetic susceptibilities for long-term management. It offers end-toend therapy, with TCM at the core of patient care.

“Our reverse drug discovery approach heralds a transformative shift, accelerating the modernization of TCM and its industrialization journey, contributing to the global medical and healthcare communities,” explains Prof. Yang.

The benefits are tangible and manifold. The approach significantly shortens the conventional drug development cycle, expediting the transition from concept to market. Reduced research and development (R&D) costs improve the economic viability of new drug ventures. It also elevates the safety and efficacy standards of new medications, resulting in optimal treatment outcomes for patients.

A nuanced understanding of development processes and safety standards enables HiST Pharma to scale its operations and push the boundaries of pharmaceutical innovation. But how does a small player like HiST Pharma contend with industry giants? The answer lies in the company’s operational blueprint—a project-based strategy that can be compared to Defense Advanced Research Projects Agency (DARPA) systematic structure.

The emphasis here shifts from individual ownership to collective project objectives, focusing on assembling skilled teams for specific project needs and ensuring efficient navigation through various stages of drug development. HiST Pharma, being small and unencumbered by bureaucratic red tape, avoids the overhead often associated with multinational corporations, streamlining the journey from idea to commercialization.

In an industry where costs can spiral into billions, HiST Pharma produces remarkable results at a fraction of the IND cost incurred by multinational pharmaceuticals. Modernizing TCM development accelerates industrialization and contributes significantly to the global medical and health community.

Leveraging Multi-Targeted Immune Rebalance with TC Cream

Derived from the natural botanical Cnidium monnieri fruit, TC Cream locally and systematically rebalances the immune responses and restores immune homeostasis. Unlike conventional drugs focusing on individual immune cells and cytokines, TC’s unique mechanism targets multiple inflammation signaling pathways, fostering antiinflammatory effects while inhibiting pro-inflammatory mediators. This multi-target approach impacts various levels and systems of a body, offering a holistic alternative to conventional therapies.

One of TC’s key advantages is its impeccable safety profile, which makes it suitable for even pediatric patients as young as two years. It broadens the applicability of the disease and positively influences those seeking effective and safe treatment options. The blend of natural plant- derived compounds with modern pharmacy methods ensures both efficacy and minimal toxicity. The product can also be used with biologics, giving patients a complementary option that does not interfere with primary treatments.

The developmental journey of TC Cream has been nothing short of remarkable. Following a successful Phase IIb trial in the U.S., the FDA authorized HiST Pharma for an expanded Phase III trial, establishing the product as the world’s inaugural botanical drug for psoriasis treatment.

A Holistic Approach to Treatment

The empirical evidence strongly suggests that the benefits of TC-based derivative drugs extend well beyond psoriasis, showing promising results in treating other immunemediated inflammatory conditions like atopic dermatitis (AD). Notably, scalp psoriasis, a particularly challenging variant often overlooked due to limited therapeutic options, has become the focus of HiST Pharma’s latest endeavors. The company is also developing drugs for nail psoriasis, offering effective therapeutic solutions for affected patients. HiST Pharma is looking to expand its therapeutic reach beyond psoriasis to include other inflammatory conditions beyond skin.

By leveraging the vast potential of TC-based derivatives, the firm is committed to providing comprehensive treatment options for a spectrum of skin ailments. Since approximately 90 percent of psoriasis patients are initially prescribed topical creams, TC Cream’s market potential is substantial in both inpatient and outpatient settings. It aligns with the growing need for accessibility and convenience, especially in the wake of telemedicine. The product mitigates the need for invasive procedures or frequent medical consultations through topical application. Individuals can order TC Cream from popular online marketplaces and take charge of their health from the comfort of their homes. The product democratizes access to quality healthcare by providing straightforward instructions for self-administration.

As the Phase III trial advances with the U.S. FDA, HiST Pharma edges closer to revealing the benefits of TC Cream to millions grappling with this debilitating disease worldwide.

Triumphs in Treatment

TC Cream has transformed the lives of many patients, relieving them of the burdensome symptoms of psoriasis and providing hope for a better quality of life. Among its numerous success stories is the inspiring account of an elderly woman afflicted by severe psoriasis, with her entire body covered in patches.

Clinical trials in the U.S. and China often exclude elderly participants due to the complexities of their immune systems and associated risks. Despite these challenges, Prof. Yang was determined to relieve the woman’s suffering. The oncewidespread psoriasis plagues disappeared with the proper administration of TC Cream, showcasing the product’s potency and unparalleled safety profile.

Another compelling story involves Daniel, an independent board member at HiST Pharma. His immune system weakened after administering five COVID-19 vaccine doses, resulting in eczema all over his body. Facing discomfort due to constant itching and recurrent infections, he sought guidance from Prof. Yang and began using TC Cream. Daniel experienced a remarkable transformation within two to three months as it healed the eczema-infected areas and brought him comfort and relief.

Prof. Yang discusses the potency of TC Cream, stating, “Our success with TC showcases the vast potential of botanical-based drugs. HiST Pharma’s groundbreaking pathway paves the way for safer clinical compounds and heralds a new era of efficacy in treatment design using small molecules.”

HiST Pharma’s journey from a visionary idea to a potential global healthcare leader demonstrates the power of TCM wisdom with modern science. Through innovative approaches like reverse drug discovery and proactive prevention, it addresses unmet medical needs and improves patient outcomes. As HiST Pharma looks forward, it focuses on drug safety, efficacy, and patient-centered care. On the verge of transforming the healthcare landscape, the company provides countless individuals with a better quality of life worldwide.